Skip to main content
    F

    Fennec Pharmaceuticals Inc (FENC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.76
    +1.14 (+9.81%)

    Market Cap: $410.25M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Fennec Pharmaceuticals Inc (FENC) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Fennec Pharmaceuticals (FENC) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Fennec Pharmaceuticals reported EPS of $0.12, above the $0.09 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    31%(11/36)
    Avg Surprise
    -40.31%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.15
    Range$0.09 - $0.24
    8 analysts
    Revenue Consensus
    $21.93M
    Range$19.46M - $23.63M
    8 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.12
    Range$0.11 - $0.13
    2 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.11+9.1%
    60d ago$0.11+12.5%
    30d ago$0.11+12.5%
    7d ago$0.11+12.5%
    Current$0.12
    Revenue Consensus
    $22.47M
    Range$21.90M - $22.80M
    3 analysts

    Next Report

    FENC has an expected report date of Mar 22, 2027.

    FENC Earnings Call

    The latest FENC earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 36 quarters below that had an estimate, FENC beat 11, missed 20 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $19.61M, up 57.4% from $12.46M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.12$0.09$0.06 - $0.16+33.33%BeatN/A51 up, 2 downNov 12, 2026$19.61M
    Jun 30, 2026$0.05$0.01$0.00 - $0.05+400.00%BeatN/A50 up, 2 downAug 11, 2026$17.87M
    Mar 31, 2026$0.01$0.03-$0.13 - $0.11-70.24%MissN/A60 up, 5 downMay 14, 2026$15.11M
    Dec 31, 2025-$0.10$0.04-$0.01 - $0.06-350.00%MissN/A50 up, 0 downMar 24, 2026$13.78M
    Sep 30, 2025-$0.02-$0.02-$0.09 - $0.040.00%In lineN/A20 up, 0 downNov 13, 2025$12.46M
    Jun 30, 2025-$0.11-$0.03-$0.07 - $0.00-266.67%MissN/A41 up, 0 downAug 14, 2025$9.65M
    Mar 31, 2025-$0.04-$0.08-$0.13 - -$0.05+50.00%Beat-109.8%42 up, 1 downMay 13, 2025$8.75M
    Dec 31, 2024-$0.06-$0.13-$0.19 - -$0.09+53.85%BeatN/A41 up, 0 downMar 10, 2025$7.92M
    Sep 30, 2024-$0.21-$0.08-$0.14 - -$0.02-162.50%MissN/A40 up, 0 downNov 7, 2024$6.97M
    Jun 30, 2024-$0.20$0.02-$0.24 - $0.42N/AN/AN/A60 up, 0 downAug 13, 2024$7.26M
    Mar 31, 2024$0.41-$0.04-$0.08 - $1.54N/AN/AN/A50 up, 0 downMay 14, 2024$25.38M
    Dec 31, 2023-$0.10-$0.02-$0.10 - $0.03-400.00%MissN/A51 up, 0 downMar 21, 2024$9.73M
    Sep 30, 2023-$0.07-$0.13-$0.15 - -$0.07+46.15%BeatN/A60 up, 0 downNov 6, 2023$6.51M
    Jun 30, 2023-$0.21-$0.16-$0.20 - -$0.09-31.25%MissN/A60 up, 0 downAug 3, 2023$3.33M
    Mar 31, 2023-$0.23-$0.19N/A-21.05%MissN/A51 up, 0 downMay 11, 2023$1.68M
    Dec 31, 2022-$0.26-$0.26-$0.33 - -$0.170.00%In lineN/A60 up, 0 downMar 30, 2023$1.53M
    Sep 30, 2022-$0.31-$0.19-$0.22 - -$0.14-63.16%MissN/A60 up, 0 downNov 11, 2022N/A
    Jun 30, 2022-$0.19-$0.13-$0.16 - -$0.11-46.15%MissN/A30 up, 1 downAug 12, 2022N/A
    Mar 31, 2022-$0.14-$0.14-$0.15 - -$0.130.00%In lineN/A21 up, 0 downMay 12, 2022N/A
    Dec 31, 2021-$0.18$0.75-$0.20 - $3.52-124.00%MissN/A40 up, 0 downFeb 28, 2022N/A
    Sep 30, 2021-$0.16-$0.14N/A-14.29%MissN/A44 up, 0 downNov 10, 2021N/A
    Jun 30, 2021-$0.15-$0.18-$0.20 - -$0.17+16.67%BeatN/A5N/AAug 10, 2021N/A
    Mar 31, 2021-$0.19-$0.38N/A+50.00%BeatN/A2N/AMay 13, 2021N/A
    Dec 31, 2020-$0.13-$0.19-$0.19 - -$0.19+31.58%BeatN/A1N/AMar 30, 2021$170000
    Sep 30, 2020-$0.24-$0.19-$0.21 - -$0.16-26.32%MissN/A3N/ANov 16, 2020N/A
    Jun 30, 2020-$0.21-$0.17-$0.22 - -$0.15-23.53%MissN/A3N/AAug 5, 2020N/A
    Mar 31, 2020-$0.19-$0.18-$0.21 - -$0.17-5.56%MissN/A3N/AMay 14, 2020N/A
    Dec 31, 2019-$0.18-$0.11-$0.16 - -$0.10-63.64%MissN/A3N/AFeb 14, 2020N/A
    Sep 30, 2019-$0.09-$0.19-$0.26 - -$0.13+52.63%BeatN/A3N/ANov 12, 2019N/A
    Jun 30, 2019-$0.24-$0.13-$0.15 - -$0.13-84.62%MissN/A3N/AAug 9, 2019N/A
    Mar 31, 2019-$0.13-$0.14-$0.19 - -$0.13+7.14%BeatN/A3N/AMay 9, 2019N/A
    Dec 31, 2018-$0.15-$0.14-$0.17 - -$0.10-7.14%MissN/A3N/AMar 13, 2019N/A
    Sep 30, 2018-$0.14-$0.14N/A0.00%In lineN/AN/AN/ANov 13, 2018N/A
    Jun 30, 2018-$0.14-$0.09N/A-55.56%MissN/AN/AN/AAug 13, 2018N/A
    Mar 31, 2018-$0.09-$0.11N/A+18.18%BeatN/AN/AN/AMay 14, 2018N/A
    Dec 31, 2017-$0.14-$0.14N/A0.00%In lineN/A1N/AMar 26, 2018N/A
    Sep 30, 2017-$0.15-$0.04N/A-275.00%MissN/AN/AN/ANov 13, 2017N/A
    Jun 30, 2017-$0.11-$0.05N/A-120.00%MissN/AN/AN/AAug 11, 2017N/A
    Mar 31, 2017-$0.08N/AN/AN/AN/AN/AN/AN/AMay 12, 2017N/A
    Sep 30, 2016-$0.04N/AN/AN/AN/AN/AN/AN/ANov 14, 2016N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.27, after -$0.06 the year before. It was -$0.06 for the year ended Dec 31, 2015, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.27N/A
    Dec 31, 2024-$0.06N/A
    Dec 31, 2023-$0.61N/A
    Dec 31, 2022-$0.90N/A
    Dec 31, 2021-$0.68N/A
    Dec 31, 2020-$0.77N/A
    Dec 31, 2019-$0.64N/A
    Dec 31, 2018-$0.52N/A
    Dec 31, 2017-$0.61N/A
    Dec 31, 2015-$0.06N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,900 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,9057
    2026Q2Jun 30, 20265,5079
    2026Q1Mar 31, 20264,77310
    2025Q4Dec 31, 20256,6839
    2025Q2Jun 30, 20254,9906
    2025Q1Mar 31, 20254,6147
    2024Q4Dec 31, 20244,5977
    2024Q3Sep 30, 20243,3215

    2026Q3 Earnings Call

    Opening remarks

    Robert C. Andrade CFO Thank you, operator, and good morning, everyone. Thank you for joining us. We are pleased to host Fennec Pharmaceuticals' third quarter 2026 earnings conference call today, during which we will review our financial results as well as provide a general business update. Joining me from Fennec this morning is our chief executive officer and board member, Jeffrey S. Hackman. Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. References to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the U.S. Securities and Exchange Commission. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on our website, www.fennecpharma.com, where it will be available for the next 30 days. And with that, I will now turn the call over to Jeffrey S. Hackman.

    Jeffrey S. Hackman CEO Thank you, Robert, and good morning, everyone. Thank you for joining us here today. We are pleased to report yet another quarter of revenue growth, reflecting continued progress across our business and the positive momentum that we are building around PEDMARK. As we look ahead, we remain focused on executing our commercial strategy, strengthening the evidence supporting the use of PEDMARK, and expanding opportunities to reach more patients who may benefit from this treatment. Today, I would like to highlight two significant areas of progress from the quarter. First, we are realizing the benefits of the investments that we made in Project Ignite, which is a strategic expansion of our sales organization. We made this investment in the first quarter of the year. We invested in 14 territories and four frontline managers to expand our ability to engage healthcare professionals, support the adoption of our product, and strengthen our commercial presence across priority markets. We now have two full quarters in the field with our new territory managers, and they are delivering productivity gains. Greater efficiency is enabling us to reach more healthcare professionals and engage them more frequently across our targeted segments. We are seeing strong uptake in the community with oncologists, and we remain focused on accelerating adoption at academic centers. This momentum is strengthening our presence and relationships across these new and existing accounts.

    Frequently Asked Questions About FENC

    When is Fennec Pharmaceuticals's next earnings date?

    Fennec Pharmaceuticals's next earnings report is expected for Mar 22, 2027.

    Did FENC beat earnings estimates last quarter?

    Yes. Fennec Pharmaceuticals reported EPS of $0.12 for the quarter ended Sep 30, 2026, above the $0.09 estimate, a 33.33% surprise.

    What EPS do analysts expect from FENC next quarter?

    The consensus EPS estimate for Fennec Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.15 from 8 analysts, with estimates from $0.09 to $0.24.

    How often does FENC beat earnings estimates?

    Fennec Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -18.72%.